Loxo Oncology Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Stamford CT United States (2010)
Status: Acquired by Eli Lilly (2019)

Organization Overview

First Clinical Trial
2014
NCT02122913
First Marketed Drug
2018
larotrectinib (vitrakvi)
First NDA Approval
2018
larotrectinib (vitrakvi)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Loxo Oncology | LOXO Oncology | Loxo Oncology, Inc. | LOXO ONCOLOGY INC | Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | Loxo Oncology Medical Monitor, VP of R&D | Senior Medical Director, Loxo Oncology